EuBiologics Co., Ltd.
Research EuBiologics Co., Ltd. (206650.KQ) on Bullrun: market cap KRW 292.66B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker206650.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyKRW
- Market capKRW 292.66B
- Financial periodQ2 2026
- RevenueKRW 33.22B
- Net incomeKRW 7.50B
- Free cash flow-KRW 6.74B
- Gross margin49.0%
Valuation Snapshot
latest market cap is KRW 292.66B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 292.66B | n/a | n/a | n/a |
Dividend history
About EuBiologics Co., Ltd.
EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen presenting cell expressing TLR 4 agonist, stimulating the production of cytokines and co-stimulatory molecules.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is EuBiologics Co., Ltd.'s market cap?
EuBiologics Co., Ltd.'s market capitalization is KRW 292.66B.
What does EuBiologics Co., Ltd. do?
EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen presenting cell expressing TLR 4 agonist, stimulating the production of cytokines and co-stimulatory molecules.